Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Evotec SE before investing.

In this article, we go over a few key elements for understanding Evotec SE’s stock price such as:

• Evotec SE’s current stock price and volume
• Why Evotec SE’s stock price changed recently
• Upgrades and downgrades for EVO from analysts
• EVO’s stock price momentum as measured by its relative strength

About Evotec SE (EVO)

Before we jump into Evotec SE’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Want to learn more about Evotec SE’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Evotec SE.

Evotec SE’s Stock Price as of Market Close

As of April 17, 2025, 12:13 PM, CST, Evotec SE’s stock price was $3.650.

Evotec SE is up 11.62% from its previous closing price of $3.270.

During the last market session, Evotec SE’s stock traded between $3.595 and $3.740. Currently, there are approximately 197.80 million shares outstanding for Evotec SE.

Evotec SE’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Evotec SE Stock Price History

Evotec SE’s (EVO) price is currently up 9.28% so far this month.

During the month of April, Evotec SE’s stock price has reached a high of $3.740 and a low of $2.840.

Over the last year, Evotec SE has hit prices as high as $7.770 and as low as $2.840. Year to date, Evotec SE’s stock is down 12.26%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Evotec SE Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 16, 2025, there were analysts who downgraded Evotec SE’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Evotec SE’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Evotec SE’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Evotec SE’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Evotec SE (EVO) by visiting AAII Stock Evaluator.

Relative Price Strength of Evotec SE

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 16, 2025, Evotec SE has a weighted four-quarter relative price strength of -12.30%, which translates to a Momentum Score of 23 and is considered to be Weak.

Want to learn more about how Evotec SE is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Evotec SE Stock Price: Bottom Line

As of April 17, 2025, Evotec SE’s stock price is $3.650, which is up 11.62% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Evotec SE stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.